130 related articles for article (PubMed ID: 28024110)
41. E-cadherin and calretinin as immunocytochemical markers to differentiate malignant from benign serous effusions.
He DN; Zhu HS; Zhang KH; Jin WJ; Zhu WM; Li N; Li JS
World J Gastroenterol; 2004 Aug; 10(16):2406-8. PubMed ID: 15285029
[TBL] [Abstract][Full Text] [Related]
42. Kallikrein 4 is expressed in malignant mesothelioma--further evidence for the histogenetic link between mesothelial and epithelial cells.
Davidson B; Xi Z; Saatcioglu F
Diagn Cytopathol; 2007 Feb; 35(2):80-4. PubMed ID: 17230566
[TBL] [Abstract][Full Text] [Related]
43. Utility of Sry-Related HMG-Box Gene 10 (SOX10) as a marker of melanoma in effusion cytology.
Dermawan JKT; Underwood D; Policarpio-Nicolas ML
Diagn Cytopathol; 2019 Jul; 47(7):653-658. PubMed ID: 30794352
[TBL] [Abstract][Full Text] [Related]
44. Cytomorphology, clinicopathologic, and cytogenetics correlation of myelomatous effusion of serous cavities: A retrospective review.
Harbhajanka A; Brickman A; Park JW; Reddy VB; Bitterman P; Gattuso P
Diagn Cytopathol; 2016 Sep; 44(9):742-7. PubMed ID: 27434129
[TBL] [Abstract][Full Text] [Related]
45. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
46. Application of multicolour flow cytometry in the detection of metastatic carcinoma in serous effusions: Special emphasis in atypical cytology.
Sahu S; Gupta P; Susheilia S; Gautam U; Dey P
Cytopathology; 2021 Mar; 32(2):169-179. PubMed ID: 33040400
[TBL] [Abstract][Full Text] [Related]
47. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
Hasteh F; Lin GY; Weidner N; Michael CW
Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
[TBL] [Abstract][Full Text] [Related]
48. Diagnostic utility of MOC-31, HBME-1 and MOC-31 mRNA in distinguishing between carcinoma cells and reactive mesothelial cells in pleural effusions.
Sun Y; Wu GP; Fang CQ; Liu SL
Acta Cytol; 2009; 53(6):619-24. PubMed ID: 20014549
[TBL] [Abstract][Full Text] [Related]
49. Differential expression of jackfruit-lectin-specific glycoconjugates in metastatic adenocarcinoma and reactive mesothelial cells-a diagnostic aid in effusion cytology.
Sujathan K; Kannan S; Remani P; Pillai KR; Chandralekha B; Amma NS; Nair MK
J Cancer Res Clin Oncol; 1996; 122(7):433-6. PubMed ID: 8690755
[TBL] [Abstract][Full Text] [Related]
50. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
51. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
52. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.
Ruitenbeek T; Gouw AS; Poppema S
Arch Pathol Lab Med; 1994 Mar; 118(3):265-9. PubMed ID: 8135629
[TBL] [Abstract][Full Text] [Related]
53. Serous effusions in malignant lymphomas: a review.
Das DK
Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
[TBL] [Abstract][Full Text] [Related]
54. The significance of detecting glucose transporter 1 and calretinin in serous effusions to differentiate between carcinoma cells and reactive mesothelial cells.
Lv M; Cha N; Zou YF; Leng JH; Hao YY; Wang S
Diagn Cytopathol; 2021 Jul; 49(7):811-816. PubMed ID: 33818924
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic utility of sialosyl-Tn in discriminating carcinomatous cells from benign mesothelium in body cavity effusions.
Zimmerman RL; Fogt F; Bibbo M
Acta Cytol; 1999; 43(6):1079-84. PubMed ID: 10578981
[TBL] [Abstract][Full Text] [Related]
56. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations.
Hecht JL; Pinkus JL; Pinkus GS
Cancer; 2006 Feb; 108(1):56-9. PubMed ID: 16329115
[TBL] [Abstract][Full Text] [Related]
57. Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions.
Conner JR; Cibas ES; Hornick JL; Qian X
Cancer Cytopathol; 2014 Aug; 122(8):586-95. PubMed ID: 25044880
[TBL] [Abstract][Full Text] [Related]
58. Detection of hyperdiploid malignant cells in body cavity effusions by fluoresence in situ hybridization on ThinPrep slides.
Florentine BD; Sanchez B; Raza A; Frankel K; Martin SE; Kovacs B; Felix JC
Cancer; 1997 Oct; 81(5):299-308. PubMed ID: 9349518
[TBL] [Abstract][Full Text] [Related]
59. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
[TBL] [Abstract][Full Text] [Related]
60. Application of the International System for Reporting Serous Fluid Cytopathology (ISRSFC) on Reporting Pericardial Effusion Cytology.
Rodriguez EF; Jones R; Gabrielson M; Santos D; Pastorello RG; Maleki Z
Acta Cytol; 2020; 64(5):477-485. PubMed ID: 32422631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
